| 1 |
Thiazolidine-2,4-dione Derivatives: Programmed Chemical Weapons for Key Protein Targets of Various Pathological Conditions |
|
|
| Navriti Chadha,Malkeet Singh Bahia,Maninder Kaur,Om Silakari |
|
| Bioorganic & Medicinal Chemistry. 2015; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Models for the prediction of PPARs agonistic activity of indanylacetic acids |
|
|
| Rohit Dutt,A. K. Madan |
|
| Medicinal Chemistry Research. 2013; 22(7): 3213 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists |
|
|
| Azadeh Matin,Munikumar Reddy Doddareddy,Navnath Gavande,Srinivas Nammi,Paul W. Groundwater,Rebecca H. Roubin,David E. Hibbs |
|
| Bioorganic & Medicinal Chemistry. 2013; 21(3): 766 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Thiazolidine-2,4-diones: Progress towards multifarious applications |
|
|
| Viral S. Jain,Dhagash K. Vora,C.S. Ramaa |
|
| Bioorganic & Medicinal Chemistry. 2013; 21(7): 1599 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions |
|
|
| Balakumar, P., Kaur, T., Singh, M. |
|
| Toxicology. 2008; 245((1-2)): 49-64 |
|
| [Pubmed] [Google Scholar] |
|
| 6 |
Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions |
|
|
| Pitchai Balakumar,Tajpreet Kaur,Manjeet Singh |
|
| Toxicology. 2008; 245(1-2): 49 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
PPAR Ligands: Are They Potential Agents for Cardiovascular Disorders? |
|
|
| Pitchai Balakumar,Madhankumar Rose,Manjeet Singh |
|
| Pharmacology. 2007; 80(1): 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Peroxisome Proliferator Activated Receptor Agonists: Emerging Therapy for Cardiovascular Complications
|
|
|
| Pitchai Balakumar ., Madhankumar Rose ., Manjeet Singh . |
|
| Journal of Pharmacology and Toxicology. 2007; 2(3): 205 |
|
| [HTML Full text] [Google Scholar] [DOI] |
|
| 9 |
PPAR dual agonists: Are they opening Pandoraæs Box? |
|
|
| Balakumar, P., Rose, M., Ganti, S.S., Krishan, P., Singh, M. |
|
| Pharmacological Research. 2007; 56(2): 91-98 |
|
| [Pubmed] [Google Scholar] |
|
| 10 |
PPAR ligands: Are they potential agents for cardiovascular disorders? |
|
|
| Balakumar, P., Rose, M., Singh, M. |
|
| Pharmacology. 2007; 80(1): 1-10 |
|
| [Pubmed] [Google Scholar] |
|
| 11 |
Evolution of peroxisome proliferator-activated receptor agonists |
|
|
| Chang, F., Jaber, L.A., Berlie, H.D., OæConnell, M.B. |
|
| Annals of Pharmacotherapy. 2007; 41(6): 973-983 |
|
| [Pubmed] [Google Scholar] |
|
| 12 |
Prevention of type 2 diabetes mellitus - Current opportunities |
|
|
| Zełobowska, K., Gumprecht, J., Simońska-Cichocka, E., Zywiec, J., Skubala, A., Grzeszczak, W. |
|
| Diabetologia Doswiadczalna i Kliniczna. 2007; 7(4): 161-167 |
|
| [Pubmed] [Google Scholar] |
|
| 13 |
Rhodanine derivatives as novel peroxisome proliferator-activated receptor γ agonists |
|
|
| Liu, Q., Zhang, Y.-Y., Lu, H.-L., Li, Q.-Y., Zhou, C.-H., Wang, M.-W. |
|
| Acta Pharmacologica Sinica. 2007; 28(12): 2033-2039 |
|
| [Pubmed] [Google Scholar] |
|
| 14 |
PPARs, metabolic syndrome and cancer |
|
|
| Tang, C.-C., Chieh, K., Chen, T.-S., Hsu, S.-Y. |
|
| Journal of Internal Medicine of Taiwan. 2007; 18(5): 244-255 |
|
| [Pubmed] [Google Scholar] |
|
